Drug Combo Proves Powerful Against Lung Cancer Albany NY

A two-drug combination treatment in Albany proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

James C Arseneau
(518) 489-0044
400 Patroon Creek Blvd
Albany, NY
Robert J Smith
(518) 243-4317
1101 Nott St
Schenectady, NY
Ira Lyndon Zackon, MD
518-786-3122
PO Box 610 1003 Loudon Rd
Albany, NY
Francis W Nugent, MD
43 New Scotland Ave
Albany, NY
Vernon James King, MD
970-244-2442
43 New Scotland Ave
Albany, NY
George Dubar Wilner
(518) 262-5454
47 New Scotland Ave
Albany, NY
Stephen Hillinger
(518) 489-0044
400 Patroon Creek Blvd
Albany, NY
RANA JACOB, MD
(518) 836-3030
2125 River Road
Schenectady, NY
Syed Mehdi, MD
518-626-5935
113 Holland Ave
Albany, NY
James Charles Arseneau, MD
518-489-2607
317 S Manning Blvd Ste 330
Albany, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Prostate Cancer Albany NY
Regular exercise may help protect men from prostate cancer, says a new study. U.S. researchers looked at 190 men who had a prostate biopsy and found that those who were moderately active -- anything equivalent to walking at a moderate pace for several hours a week -- were significantly less likely to be diagnosed with prostate cancer.
- Hormone Therapy for Breast Cancer Albany NY
- Delayed Prostate Cancer Therapy Albany NY
- Side Effect Of Chemotherapy Drugs Albany NY
- Hormone Therapy for Lung Cancer Albany NY
- Risks for Childhood Cancer Survivors Albany NY
- Fungal Infection Treatments Albany NY
- Genetic Clues for Skin Cancer Therapies Albany NY
- Exercise for Breast Cancer Survival Albany NY